Ramona Nasr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ramona Nasr has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Abir Abdel Rahman
Medical Laboratory Sciences Program, Faculty of Health Sciences, University of Balamand, Beirut, Lebanon.
2 shared publications - Pascale Salameh
INSPECT-LB (Institut National de Santé Publique, d’Épidémiologie Clinique et de Toxicologie-Liban), Beirut, Lebanon
2 shared publications Chadia Haddad
Institut National de Santé Publique, d'Épidémiologie Clinique et de Toxicologie-Liban (INSPECT-LB), Beirut, Lebanon
1 shared publication- Chadia Haddad
Faculty of Medical Sciences, Lebanese University, Hadath, Lebanon
1 shared publication Elias A. Rahal
Department of Experimental Pathology, Immunology, and Microbiology, American University of Beirut, Beirut, 1107, Lebanon
1 shared publication- Elias A. Rahal
Department of Experimental Pathology, Immunology and Microbiology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
1 shared publication
Latest Publications
- Open Access
- 30 May 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (6) , 551
Assessment of Compliance with National and International Guidelines in the Empirical Management of Community-Acquired Pneumonia (CAP) in Lebanese Hospitals: A Multicenter Retrospective Cohort Study
Background: Community-acquired pneumonia (CAP) is a major cause of morbidity and mortality globally, with serious implications in Lebanon. Both international and local guidelines advocate for empirical antibiotic treatments by illness severity, yet the extent to which these are followed in Lebanese hospitals is unclear. This research examined the adherence to CAP treatment guidelines and its association with clinical outcomes. Methods: We retrospectively studied adults admitted to two Lebanese referral hospitals (Mount Lebanon University Medical Center and Ain Wazein Medical Village) from April 2011 to March 2025 with CAP. Adherence to empirical antibiotic regimens was determined based on the guidelines from the Lebanese Society of Infectious Diseases and Clinical Microbiology, American Thoracic Society/Infectious Diseases Society of America, and British Thoracic Society/National Institute for Health and Care Excellence. The outcomes assessed were in-hospital mortality, Intensive Care Unit (ICU) admission, and length of hospital stay (LOS). We used logistic and linear regression analyses, adjusting for demographic and clinical variables. Results: A total of 337 patients were included with an average age of 61 years; 53.7% were male, 51.6% were admitted to the ICU, and the in-hospital mortality rate was 27%. In general, 65.6% of the treatment regimens adhered to at least one guideline. The combination of β-lactam and macrolide was the most common, used in 87.8% of cases, while monotherapy was administered in 31.8% of cases and included β-lactam, macrolide, fluoroquinolone, and other antibiotics; most monotherapies were non-adherent to guidelines, except for selected fluoroquinolone monotherapy cases that may be considered guideline-concordant under ATS/IDSA recommendations depending on clinical context. Adherence to guidelines did not significantly affect mortality rates (25.8% vs. 29.3%), ICU admissions (52.5% vs. 50.0%), or length of stay (11.4 vs. 9.3 days). Multivariate analysis revealed that older age (OR 1.025, 95% CI 1.008–1.042) and ICU admission (OR 1.024, 95% CI 1.012–1.039) were independent predictors of adverse outcomes, whereas guideline adherence, comorbidities, and inflammatory markers were not independently linked. Surprisingly, mortality was higher among younger patients (average age 58 vs. 67 years, p < 0.001). Conclusions: Although guideline-concordant empirical therapy was prevalent in this two-center Lebanese retrospective population, it did not independently correlate with length of stay following adjustment, ICU admission, or in-hospital mortality. Patient-related and clinical factors, such as the severity of the illness, may have an impact on observed differences in outcomes, which should be taken as relationships.
- 30 May 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (6) , 551
Open AccessAssessment of Compliance with National and International Guidelines in the Empirical Management of Community-Acquired Pneumonia (CAP) in Lebanese Hospitals: A Multicenter Retrospective Cohort Study
Background: Community-acquired pneumonia (CAP) is a major cause of morbidity and mortality globally, with serious implications in Lebanon. Both international and local guidelines advocate for empirical antibiotic treatments by illness severity, yet the extent to which these are followed in Lebanese hospitals is unclear. This research examined the adherence to CAP treatment guidelines and its association with clinical outcomes. Methods: We retrospectively studied adults admitted to two Lebanese referral hospitals (Mount Lebanon University Medical Center and Ain Wazein Medical Village) from April 2011 to March 2025 with CAP. Adherence to empirical antibiotic regimens was determined based on the guidelines from the Lebanese Society of Infectious Diseases and Clinical Microbiology, American Thoracic Society/Infectious Diseases Society of America, and British Thoracic Society/National Institute for Health and Care Excellence. The outcomes assessed were in-hospital mortality, Intensive Care Unit (ICU) admission, and length of hospital stay (LOS). We used logistic and linear regression analyses, adjusting for demographic and clinical variables. Results: A total of 337 patients were included with an average age of 61 years; 53.7% were male, 51.6% were admitted to the ICU, and the in-hospital mortality rate was 27%. In general, 65.6% of the treatment regimens adhered to at least one guideline. The combination of β-lactam and macrolide was the most common, used in 87.8% of cases, while monotherapy was administered in 31.8% of cases and included β-lactam, macrolide, fluoroquinolone, and other antibiotics; most monotherapies were non-adherent to guidelines, except for selected fluoroquinolone monotherapy cases that may be considered guideline-concordant under ATS/IDSA recommendations depending on clinical context. Adherence to guidelines did not significantly affect mortality rates (25.8% vs. 29.3%), ICU admissions (52.5% vs. 50.0%), or length of stay (11.4 vs. 9.3 days). Multivariate analysis revealed that older age (OR 1.025, 95% CI 1.008–1.042) and ICU admission (OR 1.024, 95% CI 1.012–1.039) were independent predictors of adverse outcomes, whereas guideline adherence, comorbidities, and inflammatory markers were not independently linked. Surprisingly, mortality was higher among younger patients (average age 58 vs. 67 years, p < 0.001). Conclusions: Although guideline-concordant empirical therapy was prevalent in this two-center Lebanese retrospective population, it did not independently correlate with length of stay following adjustment, ICU admission, or in-hospital mortality. Patient-related and clinical factors, such as the severity of the illness, may have an impact on observed differences in outcomes, which should be taken as relationships.
- Open Access
- 4 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 43155
Impact of macrolide therapy on clinical outcomes in hospitalized pneumonia patients: a retrospective study from Lebanese hospitals
Community-acquired pneumonia (CAP) poses a high burden on Lebanese hospitals, especially when patients require Intensive Care Unit (ICU) or prolonged length of stay. Macrolides are widely used for their antibacterial properties and also downregulate systemic inflammation. This retrospective cohort study examined 337 hospitalized patients with CAP in Lebanon between April 2011 and March 2025, comparing those who received macrolide with those who did not. Findings showed that, even after controlling for comorbidities, age, and inflammatory indicators, macrolide therapy was independently correlated with a significant reduction in mortality rate (adjusted OR = 0.26; p = 0.011). However, macrolides were not associated with reductions in ICU admission and length of stay. As for the inflammatory markers, levels of erythrocyte sedimentation rate (ESR), and procalcitonin (PCT) decreased significantly after macrolide treatment, but CRP did not. Subgroup analyses revealed fewer ICU admissions with azithromycin compared to clarithromycin, and with intravenous versus oral use, though these findings should be interpreted cautiously given the observational design. Overall, macrolide treatment, particularly azithromycin, may contribute to the improvement in survival of CAP patients, especially those with high inflammatory markers or comorbidities, which suggests potential benefit in using it in the context of a combination therapy. This result supports the rationale for using macrolides in combination therapy and emphasizes prospective studies to investigate their immunomodulatory properties in the management of pneumonia.
- 4 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 43155
Open AccessImpact of macrolide therapy on clinical outcomes in hospitalized pneumonia patients: a retrospective study from Lebanese hospitals
Community-acquired pneumonia (CAP) poses a high burden on Lebanese hospitals, especially when patients require Intensive Care Unit (ICU) or prolonged length of stay. Macrolides are widely used for their antibacterial properties and also downregulate systemic inflammation. This retrospective cohort study examined 337 hospitalized patients with CAP in Lebanon between April 2011 and March 2025, comparing those who received macrolide with those who did not. Findings showed that, even after controlling for comorbidities, age, and inflammatory indicators, macrolide therapy was independently correlated with a significant reduction in mortality rate (adjusted OR = 0.26; p = 0.011). However, macrolides were not associated with reductions in ICU admission and length of stay. As for the inflammatory markers, levels of erythrocyte sedimentation rate (ESR), and procalcitonin (PCT) decreased significantly after macrolide treatment, but CRP did not. Subgroup analyses revealed fewer ICU admissions with azithromycin compared to clarithromycin, and with intravenous versus oral use, though these findings should be interpreted cautiously given the observational design. Overall, macrolide treatment, particularly azithromycin, may contribute to the improvement in survival of CAP patients, especially those with high inflammatory markers or comorbidities, which suggests potential benefit in using it in the context of a combination therapy. This result supports the rationale for using macrolides in combination therapy and emphasizes prospective studies to investigate their immunomodulatory properties in the management of pneumonia.